We present studies describing PD-1 and PD-Ls expression in neuroblastoma (NB) as well as the ongoing clinical trials aimed to determine the potential role of both anti-PD-1 and anti-PD-L1 mAbs treatments in the context of hematological and solid pediatric cancers. The gene discussed is PDCD1; the disease is childhood malignant neoplasm.